IRIS
BARONE, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.682
AS - Asia 1.678
EU - Europa 1.436
SA - Sud America 299
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 5
Totale 5.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.607
SG - Singapore 978
RU - Federazione Russa 763
CN - Cina 371
BR - Brasile 250
DE - Germania 126
VN - Vietnam 115
FI - Finlandia 112
HK - Hong Kong 106
IT - Italia 92
NL - Olanda 76
IE - Irlanda 63
UA - Ucraina 58
GB - Regno Unito 52
CA - Canada 41
SE - Svezia 38
MX - Messico 26
IN - India 21
AR - Argentina 20
FR - Francia 20
TR - Turchia 14
ZA - Sudafrica 12
CI - Costa d'Avorio 11
ES - Italia 11
BD - Bangladesh 10
JP - Giappone 10
PL - Polonia 10
ID - Indonesia 9
EC - Ecuador 7
VE - Venezuela 7
IQ - Iraq 6
CO - Colombia 5
IL - Israele 5
DZ - Algeria 4
EU - Europa 4
PK - Pakistan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
EG - Egitto 3
JO - Giordania 3
MA - Marocco 3
UY - Uruguay 3
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GM - Gambi 2
GT - Guatemala 2
KG - Kirghizistan 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PY - Paraguay 2
SA - Arabia Saudita 2
TL - Timor Orientale 2
YE - Yemen 2
AD - Andorra 1
BE - Belgio 1
BS - Bahamas 1
CM - Camerun 1
CU - Cuba 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
NP - Nepal 1
PE - Perù 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TZ - Tanzania 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.144
Salva come PNG Salva come JPEG
Città #
Singapore 434
Moscow 178
Chandler 170
Santa Clara 159
Beijing 126
Ashburn 125
Hong Kong 106
Jacksonville 100
Millbury 73
Amsterdam 70
Princeton 70
Los Angeles 60
Nanjing 60
Ho Chi Minh City 51
Munich 47
Boston 45
Dallas 33
Wilmington 30
Buffalo 29
Nanchang 29
Seattle 26
New York 25
Helsinki 22
São Paulo 22
Turku 21
Ottawa 20
Hanoi 19
Redondo Beach 19
Mexico City 16
The Dalles 16
Houston 15
Norwalk 15
Naples 13
Washington 13
Columbus 12
Rome 12
Boardman 11
Brooklyn 11
Ankara 10
Denver 10
Kunming 10
Stockholm 10
Tokyo 10
Belo Horizonte 9
Chicago 9
Da Nang 9
Falkenstein 9
Montreal 9
Napoli 9
London 8
Pune 8
Shanghai 8
Brasília 7
Falls Church 7
Frankfurt am Main 7
Jiaxing 7
Shenyang 7
Tianjin 7
Orem 6
Atlanta 5
Hangzhou 5
Manchester 5
Poplar 5
Rio de Janeiro 5
San Francisco 5
Thái Bình 5
Toronto 5
Bexley 4
Changsha 4
Chennai 4
Hebei 4
Hefei 4
Kronberg 4
Porto Alegre 4
Santo André 4
Secaucus 4
Tampa 4
Tashkent 4
Warsaw 4
Amman 3
Ann Arbor 3
Baghdad 3
Bauru 3
Betim 3
Calgary 3
Changchun 3
Charlotte 3
Curitiba 3
Dublin 3
Fortaleza 3
Guangzhou 3
Guarujá 3
Indiana 3
Istanbul 3
Karachi 3
Manaus 3
Miami 3
Montevideo 3
Natal 3
Niterói 3
Totale 2.630
Salva come PNG Salva come JPEG
Nome #
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. 124
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. 116
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 116
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial 115
Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism 114
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. 104
Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients 104
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. 102
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. 98
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 97
Freezing of gait and executive functions in patients with Parkinson's disease. 92
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 92
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. 90
Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. 89
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. 88
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 86
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. 86
RNA analysis of consensus sequence splicing mutations: implications for the diagnosis of Wilson disease. 86
Is arginine test a reliable tool for differential diagnosis of multiple system atrophy? 86
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms 83
Dopamine agonist-based strategies in the treatment of Parkinson's disease. 83
Nitric oxide-hemoglobin interaction: a new biochemical hypothesis for signal changes in fMRI 83
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 82
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. 80
Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. 80
The PRIAMO study: background, methods and recruitment. 79
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. 79
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. 79
Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. 76
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion 76
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. 75
Linkage exclusion in Italian families with hereditary essential tremor. 75
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test 74
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. 74
HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. 74
Depression rating scales in Parkinson's disease: critique and recommendations. 73
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 71
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. 70
Clinical and neurological abnormalities in adult celiac disease. 67
Dopamine receptor agonists and depression in Parkinson's disease. 67
Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. 66
HOMER1 promoter analysis in parkinson's disease: association study with psychotic symptoms 66
Amitriptyline as a prophylactic for migraine in children. 64
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. 64
Red flags for multiple system atrophy. 64
Behavioural sensitization in 6-OHDA lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB-related and JunD-related proteins 63
Dopa-responsive pseudo-orthostatic tremor in parkinsonism. 63
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 62
The status of dopamine nerve terminals in Parkinson\'s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. 61
Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration 60
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. 60
Pergolide monotherapy in the treatment of early PD. A randomized, controlled study. 58
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 58
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. 58
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 58
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. 57
Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. 56
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 56
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. 56
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. 55
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. 55
The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. 54
Headache in children, an epidemiological study. 53
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 51
Neurotransmission in Parkinson's disease: beyond dopamine. 51
Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. 49
The FRAGAMP study: environmental and genetic factors inParkinson's disease, methods and clinical features. 45
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). 44
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. 41
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. 40
null 12
Totale 5.185
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.947
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202193 0 0 0 0 0 45 11 2 13 2 19 1
2021/2022319 3 0 0 4 0 9 1 12 67 12 52 159
2022/2023410 73 35 17 25 46 33 0 38 57 66 16 4
2023/2024321 7 38 32 35 27 53 2 32 0 10 73 12
2024/20251.726 101 82 6 9 86 133 174 118 71 170 638 138
2025/20261.815 348 196 306 293 607 65 0 0 0 0 0 0
Totale 5.185